News about "AstraZeneca"

AstraZeneca Completes USD 2B Equity Investment in Summit Therapeutics

AstraZeneca has completed its USD 2 billion equity investment in Summit Therapeutics to advance ivonescimab-based cancer treatment combinations.

AstraZeneca | 06/10/2026 | By News Bureau

AstraZeneca and Daiichi Sankyo Partner with Summit on Datroway

AstraZeneca and Daiichi Sankyo enter clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types.

AstraZeneca | 05/10/2026 | By News Bureau

HUTCHMED, AstraZeneca Submit US NDA for Orpathys-Tagrisso Combination

AstraZeneca submits a US FDA NDA for Orpathys plus Tagrisso in MET-driven NSCLC following EGFR-TKI progression, supported by positive Phase 3 SAFFRON PFS and OS results.

AstraZeneca | 01/10/2026 | By News Bureau |  100

AstraZeneca's Imfinzi Combo Gets US Priority Review for MIBC

AstraZeneca’s Imfinzi and enfortumab vedotin combination has received US FDA Priority Review based on positive Phase 3 VOLGA results in muscle-invasive bladder cancer.

AstraZeneca | 28/09/2026 | By News Bureau

EU Recommends Klygefa in AChR-Positive gMG

Alexion’s Klygefa (gefurulimab) receives a positive CHMP opinion for adults with AChR antibody-positive generalised myasthenia gravis in the EU.

AstraZeneca | 21/09/2026 | By News Bureau

AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC

DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.

AstraZeneca | 16/09/2026 | By News Bureau

Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial

AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.

AstraZeneca | 10/09/2026 | By News Bureau

AstraZeneca Reports Positive Phase 3 Results for Tozorakimab in COPD

AstraZeneca’s Phase 3 OBERON and TITANIA trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations across broad patient populations, including different blood eosinophil levels and smoking statuses.

AstraZeneca | 10/09/2026 | By News Bureau |  106

US FDA Approves ETCAMAH Plus CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer

US approves ETCAMAH (camizestrant) plus a CDK4/6 inhibitor for first-line advanced HR-positive breast cancer, reducing progression or death risk by 56 percent.

AstraZeneca | 05/09/2026 | By News Bureau

EU Approves Enhertu Plus Pertuzumab as New First-Line Regimen for HER2-Positive Metastatic Breast Cancer

The European Union (EU) has approved Enhertu plus pertuzumab as a new first-line regimen for HER2-positive metastatic breast cancer, reducing progression or death risk by 44 percent.

AstraZeneca | 02/09/2026 | By News Bureau